Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Macrophage migration inhibitory factor promoter polymorphisms (−794 CATT5–8): Relationship with soluble MIF levels in coronary atherosclerotic disease subjects

Contributed equally
BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201717:144

https://doi.org/10.1186/s12872-017-0570-x

Received: 25 October 2016

Accepted: 15 May 2017

Published: 2 June 2017

Abstract

Background

We analyzed the relationship of −794 CATT5–8 MIF polymorphisms with soluble MIF in Coronary Atherosclerotic Disease (CAD) patients.

Methods

A total of 256 patients selected, on which 186 normal-coronary and 70 Coronary artery disease subjects, were recruited in the study (Retrospectively registered). Genotyping of −794 CATT5–8 polymorphisms were performed by PCR and DNA sequencing. Serum MIF levels were measured using an ELISA kit. Patients were classified by coronary angiogram, and CAD based on Gensini’s integral degree (angiographic scoring system).

Results

The allele frequency and genotype frequency of −794 CATT5–8 did not show any differences in normal-coronary subjects and CAD subjects. In CAD patients, serum MIF levels was lower in CATT (5) subjects than in CATT (7) subjects, while the genotype of −794 CATT5–8 did not show differences in serum MIF levels. In addition, we found a decrease in serum MIF levels in carriers of the (5/5) genotypes the −794 CATT5–8 MIF polymorphisms, although it was not significant. There was no relationship of CAD class and the allele frequency of −794 CATT5–8.

Conclusions

This study found no association between CAD class and −794 CATT5–8 MIF polymorphisms with soluble MIF levels in CAD Subjects.

Trial registration

NCT01750502 (November 2012, Retrospectively registered).

Keywords

Macrophage Migration Inhibitory Factor Gene polymorphisms Coronary Atherosclerotic Disease Gensini’s degree integral

Background

Coronary Atherosclerotic Disease (CAD) is characterized by atherosclerotic plaques in the vascular wall that results in vascular stenosis or plaque disruption with acute thrombotic occlusion. It occurs due to gradual cholesterol and fibrous tissue plaque in the wall of coronary artery over long period [1]. Various risk factors have been identified for CAD, such as smoking, hypercholesterolemia, hypertension, and diabetes [2].

Evidence suggests that CAD is an inflammatory process with chronic inflammation of vessel wall infiltrated by circulating immune cells, such as monocytes and macrophages [3]. Macrophage migration inhibitory factor (MIF) is a homotrimer protein with a molecular weight of 37.5 kDa, which can promote the inflammation [4]. The first experimental studies that utilized pure recombinant MIF and neutralizing antibodies established that MIF played a critical role in the inflammatory cascade leading to endotoxic shock and death [5] . Soon thereafter, it was found that the macrophage, which had been considered historically to be the “target” of MIF action, was in fact a significant source of MIF production. In the case of the macrophage, MIF promotes TNFα production, which leads to further MIF release and a re-entrant activation pathway that is required for the optimal expression of TNFα and other pro-inflammatory mediators [6]. MIF is expressed in several cell types, including monocytes, macrophages, vascular smooth muscle cells (SMCs), and cardiomyocytes [68].

As described by Jie Wu et al. [9], the MIF gene maps to chromosome 21q22.33 in human (2119 bp). There are four polymorphisms that have been mainly reported in the human MIF gene, including three Single Nucleotide Polymorphisms (SNPs) at positions −173 (rs755622), +254 (rs2096525), and +656 (rs2070766) and a 794CATT5–8 microsatellite polymorphism. Loci rs2096525 and rs2070766 are located in introns, whereas rs755622 and −794CATT5–8 are located in the promoter region of MIF [9] . Earlier studies have found that circulating MIF levels are elevated in ulcerative colitis (UC) [10], psoriasis [9] and tuberculosis (TB) [11]. Since these diseases are accompanied by persistent inflammation of varying degrees, it is possible that MIF may play a role in the development of these diseases.

Previous studies have reported that the plasma MIF level of CAD group was higher than non-CAD patients and the plasma MIF level was related to the stability of the plaque [12]. Also, we demonstrated a close association between the polymorphism of MIF on the −173 position and CAD [12]. The aim of this study was to investigate the relationship between −794 CATT5–8 MIF polymorphisms and soluble MIF levels in CAD patients.

Methods

Subjects

A total of 256 subjects were enrolled, including 186 without CAD and 70 with CAD subjects, in the period from 06/2012 to 12/2012 in our inpatient department. All patients underwent coronary angiography (CAG) interpreted by one independent radiologist. Stenosis of the left main artery [13], Left Anterior Descending (LAD) branch, Right Coronary Artery (RCA), and other major branches were evaluated. CAD patients had the evidence of atherosclerosis (i.e., ≥ 50% luminal stenosis) in at least one coronary artery or major branch segment in their epicardial coronary tree. Patients in the control group had no luminal stenosis at CAG. Patients were excluded if they had acute inflammatory diseases, tumors, autoimmune disease and severe hepatic and renal dysfunction. All participants were of Han ethnicity living in Wenzhou, a southeastern coastal city of China. This protocol was approved by the Research Ethics Committee of Wenzhou Medical University (registration number L-2013-03). All authors have identified individual participants after data collection.

Gensini score

The severity of CAD was determined by Gensini scoring system which has been previously described [14]. Briefly, if any branches of main coronary artery Left Main Artery (LM), LAD, Left Circumflex Coronary Artery (LCX) and RCA has stenosis reaching 1–24% of the internal lumen diameter, 1 point is given. Similarly, 2 is given for 25–49% stenosis, 4 for 50–74%, 8 for 75–90%, 16 for 91–99% and 32 for 100% or total occlusion. Depending on the lesion location, the single lesion score and the coefficient, the final Gensini total score was calculated.

Human genomic DNA extraction

A blood sample of 5 mL was collected into a tube containing ethylene diamine tetra acetic acid (EDTA) from the radial artery. After centrifugation, plasma was collected and stored at −80 °C until use. Genomic DNA was extracted from cells by a DNA extraction kit (Tiangen Company, Beijing, China). The isolated DNA was also stored at −80 °C.

MIF − 794 CATT5–8 genotyping

Polymorphism was genotyped by sequencing of polymerase chain reaction (PCR) product as reported previously [4, 15]. The forward primer was 5-TTGCACCTATCAGAGACC-3 and the reverse primer was 5-TCCACTAATGGTAAACTCG-3. These primers were designed to amplify a 207 bp segment of the MIF promoter region. PCR was carried out in a volume of 25 μl. The reaction conditions of PCR were as follows: initial denaturation at 95 °C for 5 min, followed by 35 cycles at 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 1 min, with final extension at 72 °C for 10 min. PCR products were revealed by agarose gel electrophoresis.

Genomic DNA was extracted from blood collected into tubes containing EDTA. The DNA of individuals previously sequenced was used as a template to generate control DNA fragments, using BigDye Terminator v1.1, in order to correlate the fragment size observed on the ABI 310 analyzer with the number of CATT repeats in the test samples [16]. (Sequenced by Shanghai Hybio BioTechnology Co., Ltd.).

Analysis of serum MIF levels

The plasma concentrations of MIF were measured using an enzyme linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions (R&D, USA).

Statistic analyses

MIF genotype and allele frequencies were analyzed using SPSS17.0 statistical software. The allele and genotype distributions were estimated by gene counting, and distribution of the polymorphic variants was tested against Hardy–Weinberg (H–W) equilibrium by χ2 analysis. Plasma MIF concentrations were expressed as means ± SD. For comparisons between two groups, we determined the significance of differences between means by t-tests. Comparisons between multiple groups were performed by ANOVA. P ≤ 0.05 was considered statistically significant.

Results

Frequencies of MIF − 794 alleles and genotypes of CAD patients and controls

There were no significant differences in age, cigarette smoking, drinking hypertension, and diabetes except gender, (P > 0.05) (Table 1) between the CAD patients and the control. Both CAD patients and controls were in Hardy-Weinberg equilibrium with MIF −794CATT5–8 genotypes’ distribution (P > 0.05). There were seven kinds of genotypes and four kinds of alleles in these two groups (Table 2). The comparative analysis of genotype and allele frequencies of −794 CATT5–8 polymorphisms between groups did not show significant differences (P > 0.05).
Table 1

Clinical and biochemical characteristics by study group

 

Control group

(n = 186)

CHD group

(n = 70)

F/×2

P value

Mean age(year)a

60.78 ± 9.26

66.71 + 10.25

1.24

0.081

Ganderb

(male/female)

84/102

44/26

6.37

0.012

cigarette smoking(%)b

31.6%

33.3%

0.236

0.627

Drinking(%)b

18.3%

24.3%

0.677

0.41

Hypertension(%)b,c

66.7%

68.6%

0.054

0.817

Hyperlipidemia(%)b,d

16.7%

37.1%

6.76

0.009

Diabetes(%)b,e

3.3%

7.1%

0.92

0.337

aData presented as mean ± SD. Student’s t-test

bChi-square

cblood pressure ≥ 140/90 mmHg

dLDL-C ≥ 120mg/dl

eFPG ≥ 7.0 mmol/l and/or OGTT 2 h FPG ≥ 11.1 mmol/l

Table 2

Genotype and allele frequencies of −794 CATT5–8 MIF polymorphisms

Polymorphisms

Genotypes/alleles

CHD group n = 70

Control group n = 186

x2

P valuea

-794CATT

5/5

11(15.7)

31(17.6)

  

6/6

16(22.9)

30(17.0)

  

7/7

3(4.3)

7(4.0)

  

5/6

22(31.4)

56(31.8)

  

5/7

10(14.3)

24(13.6)

  

6/7

8(11.4)

26(14.8)

  

6/8

0(0)

1(0.54)

0.464

0.834

5

54(38.6)

132(35.5)

  

6

62(44.3)

190(51.1)

  

7

24(17.1)

49(13.2)

  

8

0(0)

1(0.27)

0.003

0.959

aChi-square test χ2

The plasma concentration of MIF

The plasma MIF concentration of CAD group was 65.75 ± 6.32 μg/L, significantly higher than that of non-CAD group (51.13 ± 7.33μg/L, P < 0.05), as we known before [12]. MIF serum levels were similar among CATT (5), CATT (6), and CATT (7) allele carriers. (Table 3).
Table 3

The plasma MIF concentration

 

CHD group (n = 70)

Control group (n = 186)

P* value

 

mean concentration of MIF + SD

65.75 ± 6.32

51.13 ± 7.33

  

median of MIF

65.66

50.01

0.00

 
 

alleles 5 (2n = 186)

alleles 6 (2n = 252)

alleles 7 (2n = 73)

P# value

mean concentration of MIF + SD

58.68 + 7.80

60.22 + 9.77

62.09 + 5.32

 

median of MIF

58.275 + 1.42

59.75 + 0.98

61.79 + 0.51

0.373

*Student’s t-test

#Chi-square test x2

In CAD patients the plasma MIF concentration of the carriers of CATT(5) allele was significantly lower than that of the CATT(7) allele carriers (P < 0.05) (Fig. 1a). When MIF serum levels were compared among CAD patients with different genotypes, we did not observe significant difference. In the CAD patients, the plasma MIF concentration was lower in the CATT(5/5) group than CATT(6/6) and CATT(7/7) groups but the difference was not statically significant (P > 0.05) (Fig. 1b). While in normal-coronary subjects, we did not observe a correlation between MIF serum levels with allele and genotypes (P > 0.05) (data not shown).
Fig. 1

the plasma MIF concentration of carriers of MIF −794CATT5–8 alleles and genotypes in CAD patients. a The plasma MIF concentration of the carriers of CATT(5) allele was significantly lower than that of the CATT(7) allele carriers (P < 0.05). b The plasma MIF concentration was lower in the CATT(5/5) group than CATT(6/6) and CATT(7/7) groups but the difference was not statically significant (P > 0.05)

Frequencies of MIF− CATT5–8 alleles among CAD patients

Patients were classified into three subgroups according to the Gensini system. There was no difference in MIF− CATT5–8 allele frequency in CAD patients with different scores (Table 4).
Table 4

the relationship between CHD class and the allele frequency of MIF-794 CATT5−8

CHD class (Gensini’s intergral degree)

the allele frequency of MIF-794 CATT5–8

5

6

20

16

10

20–40

14

10

40

13

4

x2

1.55

Pa value

0.46

aChi-square test

Discussion

Despite the improvements in medical treatments and subsequent survival rates, CAD is still the leading cause of death worldwide [1]. In addition, it is well documented that there is strong relationship between many genetic variants and environmental factor in CAD. Therefore, the knowledge of genetic mechanisms of CAD is helpful to develop new disease prevention and treatment strategies.

Polymorphism of MIF on the −173 position has been reported in several inflammatory diseases, including ulcerative colitis (UC) [10], psoriasis [9] and tuberculosis (TB) [11]. Several studies have reported the association between MIF794CATT gene polymorphism, MIF protein level and CAD. For example in Western Mexico, MIF794CATT (6/7) genotype was found to correlate with the onset of acute coronary syndrome [17]. Lan et al. reported that discovered polymorphism of the MIF gene was associated with the severity of carotid atherosclerotic plaque [18]. In the present study, MIF794CATT gene polymorphism and CAD incidence were not significantly correlated, but in the CAD patients, CATT (5) allele carriers had lower serum MIF concentration than the other two groups. Indeed, in vitro studies found that, CATT (5) allele has the lowest level of basic and stimulated MIF promoter activity when compared to the CATT (6) and CATT (7) alleles [16, 19]. However, it is still unknown which transcription factors regulate the expression of MIF by binding to CATT gene promoter region [20].

We found that serum MIF concentrations were significantly higher in CAD patients than the non-CAD patients, which is inconsistence with the previous finding that increased incidence MIF protein concentration is related to increased incidence of CAD [12]. However, MIF794CATT5–8 allele were not associated with the severity of CAD.

Our study is based at single center and the cases are limited because of time and geographical restrictions. Further studies with bigger sample size and patients from more cities are needed to confirm this primary conclusion.

Conclusion

To sum up, there is no significant correlation between the polymorphism of 794CATT gene and the severity of CAD.

Abbreviations

CAD: 

Coronary Atherosclerotic Disease

CAG: 

Coronary Angiography

EDTA: 

Ethylene Diamine Tetra Acetic Acid

ELISA: 

Enzyme Linked Immunosorbent Assay

LAD: 

Left Anterior Descending

LCX: 

Left Circumflex Coronary Artery

LM: 

Left Main Artery

MIF: 

Migration Inhibitory Factor

PCR: 

Polymerase Chain Reaction

RCA: 

Right Coronary Artery

SMCs: 

Vascular smooth muscle cells

SNPs: 

Single Nucleotide Polymorphism

TB: 

Tuberculosis

UC: 

Ulcerative Colitis

Declarations

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Funding

The authors disclosed receipt of the following financial support for the research and authorship of this article: National Natural Science Foundation of China [Nos. 81,573,185], Natural Science Foundation of Zhejiang Province [Nos. 2014C33163], Wenzhou Municipal Science and Technology Bureau [Nos. H20140001, Nos.Y20130167].

Authors’ contributions

LQ: research design, perform experiments, collect data and analysis of data, draft manuscript. XW: perform experiments, collect data and analysis of data. ST: perform experiments, draft manuscript. LT: perform experiments, collect data and analysis of data. SW: perform experiments, collect data and analysis of data. GL: collect data, draft manuscript. LW: perform experiments, collect data and analysis of data. JW1(Jiao-Ni Wang): perform experiments, collect data and analysis of data. JW2(Jie Wang): collect data and analysis of data. JL: research design, revising manuscript. JT: research design, draft manuscript. KJ: research design, draft manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This protocol was approved by the Research Ethics Committee of Wenzhou Medical University (registration number L-2013-03).The informed consent was obtained from all participants.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiology, the Second Affiliated Hospital, Wenzhou Medical University
(2)
Department of Cardiology, Yiwu Central Hospital

References

  1. Zaiying Lu NZ, Xie Y, Hu P. Internal medicine: People's medical publishing house; 2008. p. 274.Google Scholar
  2. Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr Opin Lipidol. 2002;13(4):383–9.View ArticlePubMedGoogle Scholar
  3. Pamukcu B, Lip GY, Devitt A, et al. The role of monocytes in atherosclerotic coronary artery disease. Ann Med. 2010;42(6):394–403.View ArticlePubMedGoogle Scholar
  4. Leng L, Bucala R. Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res. 2006;16(2):162–8.View ArticlePubMedGoogle Scholar
  5. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365(6448):756–9.View ArticlePubMedGoogle Scholar
  6. Calandra T, Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179(6):1895–902.View ArticlePubMedGoogle Scholar
  7. Burger-Kentischer A, Goebel H, Seiler R, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002;105(13):1561–6.View ArticlePubMedGoogle Scholar
  8. Willis MS, Carlson DL, Dimaio JM, et al. Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury. Am J Phys Heart Circ Phys. 2005;288(2):H795–804.Google Scholar
  9. Wu J, Chen F, Zhang X, et al. Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J Dermatol Sci. 2009;53(3):212–5.View ArticlePubMedGoogle Scholar
  10. Shiroeda H, Tahara T, Nakamura M, et al. Association between functional promoter polymorphisms of macrophage migration inhibitory factor (MIF) gene and ulcerative colitis in Japan. Cytokine. 2010;51(2):173–7.View ArticlePubMedGoogle Scholar
  11. Li Y, Zeng Z, Deng S. Study of the relationship between human MIF level, MIF-794CATT5-8 microsatellite polymorphism, and susceptibility of tuberculosis in Southwest China. Braz J Infect Dis. 2012;16(4):383–6.View ArticlePubMedGoogle Scholar
  12. Ji K, Wang X, Li J, et al. Macrophage migration inhibitory factor polymorphism is associated with susceptibility to inflammatory coronary heart disease. Biomed Res Int. 2015;2015:315174.PubMedPubMed CentralGoogle Scholar
  13. Barton A, Lamb R, Symmons D, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 2003;4(7):487–91.View ArticlePubMedGoogle Scholar
  14. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.View ArticlePubMedGoogle Scholar
  15. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol. 2004;15(5):553–8.View ArticlePubMedGoogle Scholar
  16. Baugh JA, Chitnis S, Donnelly SC, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3(3):170–6.View ArticlePubMedGoogle Scholar
  17. Valdes-Alvarado E, Munoz-Valle JF, Valle Y, et al. Association between the −794 (CATT)5–8 MIF gene polymorphism and susceptibility to acute coronary syndrome in a western Mexican population; 2014. p. 704854.Google Scholar
  18. Lan MY, Chang YY, Chen WH, et al. Association between MIF gene polymorphisms and carotid artery atherosclerosis. Biochem Biophys Res Commun. 2013;435(2):319–22.View ArticlePubMedGoogle Scholar
  19. Renner P, Roger T, Bochud PY, et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J. 2012;26(2):907–16.View ArticlePubMedGoogle Scholar
  20. Radstake TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52(10):3020–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement